Alpha Synuclein Market Dynamics: Challenges and Future Potential
The evolution of clinical trial frameworks has necessitated a paradigm shift within the Alpha Synuclein Market, placing a premium on objective, quantifiable biofluid markers. For decades, definitive diagnosis of synucleinopathies could only be confirmed via post-mortem tissue autopsies. Today, the commercialization of cerebrospinal fluid (CSF) and blood-based alpha-synuclein assays is...
0 التعليقات 0 المشاركات 221 مشاهدة 0 معاينة